Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

103.66USD
12:10pm EDT
Change (% chg)

$0.93 (+0.91%)
Prev Close
$102.73
Open
$102.26
Day's High
$103.71
Day's Low
$102.26
Volume
74,683
Avg. Vol
489,261
52-wk High
$104.00
52-wk Low
$75.84

Chart for

About

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $16,617.19
Shares Outstanding(Mil.): 175.27
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.02 -- --
ROI: -5.48 15.07 14.61
ROE: -7.41 16.60 16.34

S&P, Dow fall as oil drop hurts energy; chipmakers boost Nasdaq

NEW YORK The S&P 500 and the Dow eased on Friday after a steep drop in oil prices pressured energy stocks, but losses were limited by gains in chipmakers and retail stocks.

May 25 2018

FDA approves BioMarin rare metabolic disorder drug, shares rise

U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

May 24 2018

FDA approves BioMarin rare metabolic disorder drug, shares rise

May 24 U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc's Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.

May 24 2018

BRIEF-Biomarin Announces First Patient Dosed In Phase 1/2 Study Of Treatment For Type of Hemophilia A

* BIOMARIN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY EVALUATING VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY IN SEVERE HEMOPHILIA A PATIENTS WITH PRE-EXISTING AAV5 ANTIBODIES Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

Apr 25 2018

BRIEF-Biomarin Pharmaceutical Reports Q1 Loss Per Share Of $0.25

* Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION

Apr 25 2018

BRIEF-Biomarin Pharma CEO's 2017 Compensation Was $15.9 Million

* BIOMARIN PHARMACEUTICAL INC SAYS CEO JEAN-JACQUES BIENAIMÉ'S 2017 TOTAL COMPENSATION WAS $15.9 MILLION VERSUS $16.9 MILLION IN 2016 – SEC FILING

Apr 24 2018

BRIEF-European Medicines Agency Accepts Biomarin's Marketing Application For Pegvaliase

* EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS BIOMARIN'S MARKETING APPLICATION FOR PEGVALIASE MAA FOR TREATMENT OF PHENYLKETONURIA (PKU)

Mar 28 2018

BRIEF-BioMarin Q4 GAAP Loss Per Share $0.30

* BIOMARIN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 22 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $128.77 +4.08
Pfizer Inc. (PFE.N) $37.60 +0.22
Novartis AG (NOVN.S) CHF78.20 -0.46
Merck & Co., Inc. (MRK.N) $62.55 -0.04
Roche Holding Ltd. (ROG.S) CHF232.00 -0.25
Roche Holding Ltd. (RO.S) CHF236.80 +0.20
Abbott Laboratories (ABT.N) $63.05 +1.27
Bayer AG (BAYGn.DE) €93.41 +0.24
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €71.84 +0.18

Earnings vs. Estimates